Deep learning has already had a huge impact on computer vision and speech recognition, and it’s making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine.
Deep Genomics plans to identify gene variants and mutations never before observed or studied and find how these link to various diseases. And through this work the company believes it can help usher in a new era of personalized medicine.
Genomic research is hard. Scientists still know relatively little about our genes and how they interrelate. But Frey and others in the field now know enough that they can equip machines to do the heavy lifting. And there’s an awful lot of this heavy lifting to do. “Genomics is no longer about small datasets,” Frey tells Gizmag. “It’s now about very, very large datasets.”
For context, the first effort to sequence a full human genome took 13 years – running from 1990 to 2003. There are now many companies working to sequence many genomes at a time. The largest of these is called Illumina. “Illumina,” Frey says, “expects to sequence one million genomes in the next year. Each genome contains three billion letters. That’s a lot of data.”
To store and make sense of all that data, Deep Genomics built Spidex. The name is a portmanteau of “splicing index,” which basically means that Spidex is a database containing information about how lots and lots of different genetic variants affect (or are likely to affect) RNA splicing – a crucial step in gene expression that edits genes in different ways so that they can produce different kinds of proteins.
If RNA splicing goes off kilter, the consequences could range from nothing in particular to disease and cancer. Spidex is meant to help us separate the harmless variants from the harmful ones, and to understand how they relate to other genetic processes.
Spidex currently includes predictions to the tune of around 328 million such variants and the knock-on effects they pose for RNA splicing. That number is set to grow as the company applies its deep learning algorithms to classifying and interpreting more data.
Frey also notes that the bulk of those variants are in the “junk DNA” part of the genetic code. This is the bit that scientists had previously written off as irrelevant, even though it forms the vast majority of the genome. “Most medical genetic analysis currently deals only with mutations in what are called ‘protein-coding segments’ in DNA, or ‘exons,’ Frey explains. “This makes up only 1.5 percent of the genome.”
Read more: New company plans to revolutionize genomic medicine with deep learning
The Latest on: Genomic medicine
[google_news title=”” keyword=”Genomic medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genomic medicine
- Genomics Week in Brief: Week Ending 24th Mayon May 27, 2024 at 1:48 am
Struggling to keep up with the latest news in the genomics world? We’ve got you covered! In Week in Brief, we’ve collated the biggest stories from the past seven days, so you can catch up quickly.
- Study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of US veteranson May 24, 2024 at 11:35 am
A new study led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup ...
- See How This Company Uses Artificial Intelligence To Decode Genomic Diversityon May 24, 2024 at 11:34 am
Decoding genomic diversity with artificial intelligence can help bridge the gap in healthcare accessibility globally.
- Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meetingon May 24, 2024 at 3:59 am
Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) ...
- Pineapple mint's genetic blueprint: A comprehensive genome assemblyon May 23, 2024 at 11:59 am
Mentha suaveolens, commonly known as pineapple mint, is valued for its distinct aroma and medicinal properties, which are attributed to its essential oils.
- Tracking the cellular and genetic roots of neuropsychiatric diseaseon May 23, 2024 at 11:00 am
A new study of nearly 400 human brains links genetic variants to genes and cell types, which could help enable precision-medicine for neuropsychiatric disease.
- EDITORIAL: Bill on genomic medicine should secure quality of new serviceson May 22, 2024 at 5:00 pm
A bill to promote genomic medicine, which involves using people’s genomic information as part of their clinical care, has passed a Lower House committee and is set to be enacted after ...
- Rare genetic diseases and genomics: past, present and future – public lecture by Professor Eamonn Maheron May 22, 2024 at 11:28 am
The Dean of Aston Medical School will give a public lecture on rare genetic diseases and new insights from genomics at Aston University on 6 June ...
- Largest genomic cancer resource accelerating research and drug developmenton May 20, 2024 at 5:01 pm
Dr Gianmarco Contino, Head of c-StAR lab, Associate Professor of Cancer Genomic Medicine and Consultant Upper GI Surgeon at the University of Birmingham, said “On a daily basis, the COSMIC catalogue ...
- Study identifies genetic link between inflammatory bowel disease and Parkinson's diseaseon May 14, 2024 at 7:35 am
Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and Parkinson's disease (PD).
via Bing News